The X-men are here already – albeit at the micron scale. Several of 2016’s blockbuster movies, such as X-Men: Apocalypse, Deadpool, and Captain America: Civil War, envision a world where mutants use their powers for the greater good. In 2013, articles surfaced that predicted individuals with powers such as Wolverine, Spiderman and Deadpool could be part of everyday society by 2045. Three years later, some individuals with beneficial mutations are already among us--although you won't be able to see them with the naked eye. For now, these heroes are mainly E. coli and yeast. Using the powerful tools offered through organism engineering, simple prokaryotes and eukaryotes are being built with powers that benefit humanity.
Topics: Synthetic Biology
As part of our continuing synthetic biology conversations series, we spoke with Saji Wickramasekara, Founder and CEO of Benchling, a San Francisco-based company working to make life science research faster and more collaborative. The following is part two of our two-part conversation with Saji.
As part of our continuing synthetic biology conversations series, we spoke with Saji Wickramasekara, Founder and CEO of Benchling, a San Francisco-based company working to make life science research faster and more collaborative. The following is part one of our two-part conversation with Saji.
A few weeks back, we announced that we'd signed a partnership with Ginkgo Bioworks to deliver 300 million base pairs of DNA through 2017. This unprecedented deal has been thought-provoking in many ways, and we’ve had some great questions arise from the synbio community and beyond. What will Ginkgo do with 300 megabases of content? How can Gen9 manufacture all that DNA? What could I do with pathway-length constructs like the ones Ginkgo uses?
We sat down with leaders at Ginkgo and Gen9 to learn more about what the partnership means for the future of synthetic biology.
Earlier today, we announced some exciting news for the field of synthetic biology. We’re teaming up with Ginkgo Bioworks to supply 300 million base pairs of synthetic DNA between now and the end of 2017. In this unprecedented deal, we will provide Ginkgo with massive quantities of pathway-length DNA constructs for use in their organism engineering platform.
Topics: Synthetic Biology
Topics: DNA Design
Last week, we announced the next generation of our BioFab® technology, an advancement that enables us to manufacture mass quantities of high quality, long-length, clonal DNA at prices as low as 3 cents per base pair. These game-changing economics will open doors for industrial users as they utilize megabase quantities of DNA on their journey towards new product discovery.